278 results about "Enoxolone" patented technology

A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.

The invention relates to a novel liver target drug carrier-glycyrrhetinic acid-polyethylene glycol/chitosan or chitosan derivative liver target compound drug delivery system. During the preparation of the nano-drug delivery system, the liver target small-molecule glycyrrhetinic acid is firstly used for modifying amino polyethylene glycol by the different sites, then a water soluble big-molecule liver target compound is prepared and is mixed with a solution containing chitosan or chitosan derivative by a certain proportion, an ion cross-linking agent is added under the stirring condition, and a target group is introduced at the same time of the spontaneous formation of nanoparticles by physical winding and electrostatic interaction. The method of introducing the target group of the invention is novel, the formation of spheres is simple, the conditions are moderate, and the content of the target group is high (the weight percentage of glycyrrhetinic acid is 5 to 30 percent). The drug delivery system has strong killing capacity to the cancer cells, the in vitro experiments show that the drug delivery system has very strong binding capacity with the liver cells, and the high content of the target group can improve the liver target capacity of the drug delivery system, realize the target positioning of the liver and open a new way for the treatment of liver cancer.

The invention relates to a plant active component composition with slow anti-allergic action. The plant active component composition is mainly prepared from natural plant active components: 0.1-5wt% of glycyrrhetinic acid, 0.05-1wt% of apigenin, 0.05-1% of table gallic catechin gallic acid ester, 0.1-3wt% of asiaticoside, 0.1-5wt% of baicalin and 0.1-10wt% of fucus serratus extract. The composition is used for preparing cosmetics or personal care products with a plurality of effects of resisting skin allergy, diminishing inflammation, relieving itching, resisting oxidation, moisturizing and the like. The composition is safe and free of toxic and side effects, and can be compounded with a plurality of components, sensitive skin and dry skin are effectively improved, and the barrier function of the skin is reinforced.

The invention discloses a novel glycyrrhetinic acid derivative, and a preparation method and medicinal uses thereof. The glycyrrhetinic acid derivative is a compound prepared by coupling nitric oxide donor of furazan nitrogen oxides and glycyrrhetinic acid through ester bonds or amide bonds. As proved by pharmacological experiments, the glycyrrhetinic acid derivative has superior antitumor effectand can be used for the preparation of antitumor medicines.

The invention discloses a hepatic targeted temperature sensitive microsphere and a preparation method therefor, and belongs to the functional polymer material field, and especially relates to a drug sustained release and targeted drug delivery material and a preparation method therefor. The temperature response range of the material is 25 DEG C-37 DEG C, and the particle size of the microsphere is about 500nm. The microsphere can be prepared through the following method: glycyrrhetinic acid (GA) is modified by ethylene diamine and acrylic acid (AAc) and vinyl monomers are generated; ammonium persulfate (APS) is employed as an initiator, N,N-methylene bisacrylamide (MBA) is employed as a cross-linking agent, hepatic targeted temperature sensitive microspheres are prepared through a semicontinuous soap-free emulsion polymerization method. The preparation method has simple technological processes, and mild experiment conditions, needs no special devices, has a low investment cost, and has good operability. The reagents are all common reagents. The reaction residues are easy to remove. The preparation method is convenient for industrial implementation.

The invention discloses a medicine for treating pruritus caused by dermatitis, eczema and insect bite, and applications thereof. The medicine is a preparation prepared by the following components according to weight percentage: 0.1 percent to 90 percent of glycyrrhizic acid or physically acceptable salt of glycyrrhizic acid or glycyrrhetic acid or physically acceptable salt of glycyrrhetic acid, 0 percent to 90 percent of total matrines or physically acceptable salt of total matrines or oxymatrine or physically acceptable salt of oxymatrine or matrine or physically acceptable salt of matrine, 0 percent to 90 percent of hibiscus syriacus acid or physically acceptable salt of hibiscus syriacus acid or pseudolaric acid B or physically acceptable salt of pseudolaric acid B or osthole or total coumarins of fructus cnidii, and 1 percent to 5 percent of menthol or borneol. The medicine has the effect of anti-inflammatory, bacteriostasis and relieving itching, has unique therapeutic effect on pruritus caused by dermatitis, eczema and insect bite. The raw materials used by the medicine are nontoxic and cheap with low cost.

A sodium alginate liver-targeted nanometer drug delivery system uses sodium alginate as carrier material and uses glycyrrhetic acid as liver-targeted compound. The single-end-modified glycyrrhetic acid-ethylene diamine is prepared through the reacting between the carboxy group of glycyrrhetic acid and the ethylene diamine. The glycyrrhetic acid-sodium alginate is prepared through the reacting between the carboxy group of sodium alginate and the amino group of glycyrrhetic acid-ethylene diamine. Finally the sodium alginate liver-targeted drug delivery nanometer particles are prepared through crosslinking the glycyrrhetic acid-sodium alginate through calcium ions. The invention has a beneficial effect that the liver-targeted nanometer drug delivery system prepared by the invention has high liver targeting property. The hydrophilic anticancer drug and hydrophobic anticancer drug can be packaged simultaneously or a single anticancer drug is packaged. The sodium alginate liver-targeted nanometer drug delivery system of the invention has the advantages of sustained-releasing function of drug, reduced drug dosage, reduced drug taking times, reduced toxic-side effect of drug, increased drug effect, simple and practical preparing method, and excellent application prospect.

The invention relates to high-effective mosquito repelling liquid medicine which is characterized by comprising the following components by weight percent: 2%-7% of N, N-Diethyl-m-toluamide, 0.2%-2% of glycyrrhiza extract (0.1%-90% of glycyrrhizinic acid or glycyrrhetinic acid or physiologically acceptable salt thereof), 0.2%-2% of flavescens extract (0%-90% of matrine or oxymatrine or physiologically acceptable salt thereof), 0%-50% of menthol or borneol and 0.01%-2% of plant essential oil. The high-effective mosquito repelling liquid medicine is the hormone-free preparation made of pure Chinese herbal medicine for external application and is prepared by uniquely combining the high-effective repellent with the components having the anti-inflammatory, the antibacterial and the antipruritic effect, thereby being innovative. The high-effective mosquito repelling liquid medicine of the invention has the function of repelling the mosquito, relieving the itching, refreshing the consciousness and protecting the skin from the insect bite and can repel the mosquito for 5-7 hours. The high-effective mosquito repelling liquid medicine of the invention is non-toxic to the skin and mucous membrane, can not cause the allergic reaction and has higher stability.

The present invention provides one new kind of glycyrrhetic acid derivative with high water solubility, high absorption, no irritation to blood vessel and capacity of being prepared into injection, and its preparation process, medicinal composition and preparation. The glycyrrhetic acid derivative has excellent treating effect on acute and chronic hepatitis, bacterial hepatitis, viral hepatitis, cerebral ischemia/re-perfusion damage, brain injury and myocardial ischemia/re-perfusion damage.

A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a drug dissolved or dispersed in an aqueous medium. The aqueous medium consists essentially of water, about 3% to about 10% w/v polyvinylpyrrolidone, about 60% to about 75% w/v of C₃-C₆ polyol that includes more than 55% w/v of a non-reducing disaccharide, trisaccharide or tetrasaccharide such as sucrose, optionally about 0.01% to about 0.5% w/v of a glycyrrhetic acid, glycyrrhizinate derivative or salt thereof, and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is room temperature stable, and may have a pleasant taste.

Disclosed are cosmetic preparations and, more particularly, skin and hair care and cleaning products with an amount of at least one glycyrrhetic antibacterial agent selected from glycyrrhetic acid, glycyrrhetic acid derivatives and extracts of Glycyrrhiza glabra, and their salts, effective to inhibit or prevent the growth of bacteria. The cosmetic preparations may include other antibacterial or antibiotic agents. The glycyrrhetic antibacterial agent and, optionally, the antibacterial or antibiotic agents may be provided in microencapsulated form. Also disclosed is the use of such cosmetic preparations for treating acne.

Disclosed are nitrate derivant of glycyrrhizic acid or glycor represented by formula Ia and Ib and its nontoxic salt which can be accepted in the sphere of pharmacy, their precoss for preparing, and components and usage of the drugs which contain these compounds.Thereinto, R1, R2 and R3 stand for hydroxyl or -X-L-oxo-oxonitryl (X stands for oxygen,imino; L stands for alkyl with 2-6 of canbon atoms, substituted alkyl or cycloalkyl, hydroxyl amino acid residue or N,Ní»-disubstituted piperazine); R3 stands for hydrogen, oxonitryl or carbonyl -Lí»oxo-oxonitryl (Lí»stands for alkyl with 1-6 of canbon atoms, substituted alkyl or cycloalkyl, aralkyl, N,Ní»-disubstituted piperazine); in formula Ib, R1, R2 and R3 may be the same or different, but in which at least one of them contains -X-L-oxo-oxonitryl; in formula Ib, at least one of R3 or R4 must contain oxonitryl. In formula Ia and Ib, hydrogen of 18-carbon can be alpha-isomer or beta-isomer.

The present application relates to: (a) compounds of Formula (I):

and salts thereof, wherein Y and Z are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

The invention provides a paeoniflorin and glycyrrhetinic acid composition and a preparation method and application thereof for treating rheumatoid arthritis and eczema. The composition comprises paeoniflorin and glycyrrhetinic acid in a weight part ratio of 1:0.25-10. The composition can be prepared into various pharmaceutical formulations such as tablets, capsules, pills and the like; and the composition and other active ingredients form amulti-ingredient medicinal composition for providing a medicament with convenient administration and definite effect. The composition has good effect of treating rheumatoid arthritis and eczema.

The present invention relates to the application of glycyrrhizic acid and glycyrrhetic acid in preparing medicine for inflammatory enteropathy. Glycyrrhizic acid and glycyrrhetic acid possess the functions of inhibiting inflammation reaction and resisting oxidation, so that the medicine of glycyrrhizic acid or glycyrrhetic acid has high curative effect on inflammatory enteropathy, high safety and other advantages.

The invention discloses composition of a paeoniflorin- glycyrrhetinic acid transdermal patch and a method for preparing the same. The transdermal patch consists of a lining, a drug-carrying pressure sensitive adhesive layer and an anti-sticking layer, wherein the drug-carrying pressure sensitive adhesive layer comprises the following ingredients in part by weight: 1 to 20 parts of paeoniflorin and 1 to 20 parts of glycyrrhetinic acid or 5 to 30 parts of extract of paeoniflorin and 5 to 30 parts of extract of glycyrrhetinic acid, organic alkali, a penetration enhancer and butyl alcohol. The content of the paeoniflorin of the extract of paeoniflorin and the content of the glycyrrhetinic acid of the extract of glycyrrhetinic acid are 20 to 90 percent respectively. The main active ingredients of common peony and liquorice can enter skin and subcutaneous tissues by transdermal penetration to effectively alleviate and inhibit spasm and pain in local tissues.

The invention relates to a hydrogel preparation for improving the permeation of an active component glycyrrhetinic acid and/or its salt through a barrier via skins, its preparation method, and its application in the dermatology. The glycyrrhetinic acid hydrogel preparation comprises 0.01-10wt% of the active component glycyrrhetinic acid and/or its salt, 0.01-10wt% of a gel matrix, 0.01-10wt% of a humectant, 0.01-5wt% of an antiseptic, 0.01-5wt% of a pH adjustment agent, and the balance water. The glycyrrhetinic acid hydrogel preparation has the advantages of simple preparation method, good storage stability, substantial improvement of the penetration amount through the skins, no irritation or anaphylaxis, good absorbency, and good safety, and can be used for preparing medicinal preparations for treating dermatoses comprising chronic urticaria, eczema, contact dermatitis and the like through skin administration.

The invention relates to a lactose acidized glycyrrhetinic chitosan material and a preparation method and the application thereof. The lactose acidized glycyrrhetinic chitosan material is a glycyrrhetinic acid and lactobionic acid jointly modified chitosan material which is synthesized through N-acylation reaction with chitosan serving as carrier and glycyrrhetinic acid and lactobionic acid serving as ligands. The invention further provides a lactose acidized glycyrrhetinic chitosan/5-fluorouracil medicine carrying nano particle. The lactose acidized glycyrrhetinic chitosan material and the preparation method and the application thereof have the advantages that the dual-ligand co-modified chitosan material is synthesized for the first time, and the nano particle is prepared for target research; and the lactose acidized glycyrrhetinic chitosan which is prepared into the nano particle has higher liver targeting performance and hepatoma cell receptor mediate initiative targeting performance as compared with GA (glycyrrhetinic acid )-CTS (chitosan) and CTS, distribution in other visceral organs can be evidently reduced, reliability in hepatoma targeting is improved, and the lactose acidized glycyrrhetinic chitosan material can be used as a carrier material which has wide application prospect in clinical hepatoma targeted treatment.

The invention discloses novel organic berberine glycyrrhetinic acid enantiomeric salts used for medicines and a production method and application thereof. The chemical name of the organic berberine glycyrrhetinic acid enantiomeric salts is: 5,6-dihydrogen-9,10-dimethoxybenzo[g]-1,3-benzodioxolane[5,6-a]quinolizidine.18a(beta),3beta-hydroxyl-11-oxooleanane-12-olefine-30-formate. The production method comprises the following steps of: respectively dissolving berberine and a glycyrrhetinic acid enantiomer in 80 percent ethanol according to a medicament eutecticum principle, mixing the two liquids, stirring for 2 hours, removing the ethanol under reduced pressure, and treating by using ethyl acetate to prepare the berberine glycyrrhetinic acid enantiomeric salts. The organic salts with dual parent nuclei have positive practical significance for resisting diseases such as tumors, diabetes, chronic inflammatory diseases such as rheumatoid arthritis, hepatitis, Alzheimer disease and the like of human and developing medicines.

The present invention relates to a medicine for relieving spasm and pain and its preparation method. It utilizes medicine active matter glycyrrhetinic acid extracted from licorice and paenoiflorin extracted from peony root, and uses their respective effective amount and medicinal carrier and/or excpient to make them into the modern medicine with small volume, easy storage, convenient administration and therapeutic effect identical to that of peony licorice decoction. Said medicine also has no toxic effect.

The invention discloses a solid dispersion containing glycyrrhetinic acid 30-amide derivative active component and a preparation method thereof. The solid dispersion consists of active components and carrier materials with the weight percentage of 1: 0.5 to 1: 50. The preparation method can adopt one of the following methods: melting method, solvent method, melting-solvent method, grinding method, spray drying method or freeze-drying method. The solid dispersion can form the medical combination with one or more pharmaceutical acceptable carriers, excipient or diluents; the invention is applied in treatments of anti-inflammatory, anti-gastric ulcer, anti-colitis, analgesia, anti-tussive, liver protection and so on.

The invention discloses application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis. The glycyrrhetinic acid or the glycyrrhizic acid can be used for reducing collagen deposition of lung tissues, decreasing or delaying the occurrence of the pulmonary fibrosis, improving lung compliance and further improving pulmonary functions through inhibiting acute or chronic inflammation reaction. The medicaments prepared from the glycyrrhetinic acid or the glycyrrhizic acid for resisting the pulmonary fibrosis has the advantages of good curative effect and low toxicity during administration in long term, can be used as medicaments for preventing or treating fibrosis, and can also be used as medicines or health care products as well as foods or food additives for preventing or treating the pulmonary fibrosis.

The invention provides a pure traditional Chinese medicine compound preparation for external use (such as ointment, film agent, gel and tincture), which is used for treating pruritus caused by eczema-dermatitis and mosquito biting and does not contain hormonal. The compound is prepared from resveratrol, glycyrrhizic acid or physiologically acceptable salts of glycyrrhizic acid or glycyrrhetinic acid or physiologically acceptable salts of glycyrrhetinic acid, ginghaosu and derivates thereof, menthol or borneol composition. Proved by experiments and clinical tests, the compound resveratrol anti-inflammatory and itching relieving medicament combination has the functions of resisting inflammation, restraining bacteria and relieving itching aiming at the characteristics of pruritus caused by eczema-dermatitis and mosquito biting and has specific curative effect for pruritus caused by eczema-dermatitis and mosquito biting. The invention has the advantages of nontoxic raw materials, low price and cost, wide market prospect and considerable expectant economic benefit and social benefit.

The invention provides a method for measuring content of eighteen ingredients of Huangqi Jianzhong Wan (astragalus mongholicus pill for invigorating the stomach and regulating the middle warmer). Themethod includes the steps of subjecting the Huangqi Jianzhong Wan to ultrasonic extraction and centrifugation, extracting the liquid supernate, detecting the liquid supernate by an ultra performance liquid chromatography-tandem mass spectrometry positive and negative ion mode, preparing a mixed standard product solution from standard products of the eighteen ingredients, building a standard curve,and carrying out the methodological study. The method can realize measuring the eighteen ingredients of the Huangqi Jianzhong Wan, namely ononin, formononetin, calycosin, calycosin-7-glucoside, pterocarpan, astraisoflavan-7-O-beta-D-glucoside, isoflavane, isoliquiritin, liquiritigenin, liquiritin, glycyrrhetinic acid, cinnamic acid, isomucronulatol 7-O-beta-glucoside, astragaloside I, astragaloside II, astragaloside III, astragaloside IV and gallic acid. In the method, the sample pre-treatment process is simple and accordingly time for measurement is short; the method has the advantages of high specificity, high flexibility, good reproducibility and short analysis time, and can be applied to monitoring of production quality of the Huangqi Jianzhong Wan.